Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. [electronic resource]
Producer: 20090430Description: 431-9 p. digitalISSN:- 1534-4681
- Adenocarcinoma -- genetics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Pancreatic Ductal -- genetics
- Chemotherapy, Adjuvant
- Cisplatin -- administration & dosage
- Combined Modality Therapy
- Cyclin-Dependent Kinase Inhibitor p16
- Cyclin-Dependent Kinase Inhibitor p27 -- genetics
- DNA-Binding Proteins -- genetics
- Deoxycytidine -- administration & dosage
- Disease Progression
- Female
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Proteins -- genetics
- Nuclear Proteins -- genetics
- Pancreatic Neoplasms -- genetics
- Pancreaticoduodenectomy
- Polymorphism, Single Nucleotide -- genetics
- Prognosis
- Proto-Oncogene Proteins c-mdm2 -- genetics
- Radiotherapy, Adjuvant
- Survival Rate
- Time Factors
- Tumor Protein p73
- Tumor Suppressor Proteins -- genetics
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.